Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride potentially treats hair loss by reducing DHT production.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

This study identified several herbs, including Ganoderma lucidum and Urtica dioica, that showed promising 5α-reductase inhibitory activity suggesting potential use in managing androgenic disorders.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

This article outlines the synthesis of spiro[cyclohexane‐1,2′‐[2 H ]indene] derivatives similar to known steroid 5α‐reductase inhibitors, but it does not report experimental findings.

This review discusses plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, as potential alternatives to 5-alpha-reductase inhibitors for prostate cancer treatment, highlighting their promising anti-cancer properties and potentially fewer side effects compared to conventional drugs.

This study found that Solanum nigrum L. extracts showed potential as 5 alpha-reductase inhibitors, similar to finasteride, and highlighted their promise for treating androgenic diseases like benign prostatic hyperplasia and male pattern hair loss.

This study found no significant difference in semen parameters or reproductive hormone levels between men taking low-dose finasteride for androgenic alopecia and those not on the medication.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This review discusses the potential of 4-azasteroids as 5α-reductase inhibitors for treating hirsutism, reporting their promising effects in animal studies but noting no clinical trials have been conducted yet.

This study found that acute sleep deprivation enhanced 5α-reductase expression and activity in the rat prefrontal cortex, and finasteride treatment reduced associated psychosis- and mania-like behaviors.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This review explores plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, for their potential use as alternative treatments for prostate cancer, emphasizing their effects on 5-alpha-Reductase enzyme isozymes. It reports no new clinical results.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This study identified the expression of 5αR1 and 5αR3 enzymes in canine skin, which may advance understanding and treatment of alopecia X.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This review discusses the steroidogenic properties of human skin and suggests that impaired steroidogenesis may be linked to conditions like acne, rosacea, atopic dermatitis, and androgenic alopecia, but reports no new clinical results.

This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.

This study found that Bokusoku extract and its compound pentagalloyl glucose inhibited testosterone metabolism and sebum synthesis, suggesting potential therapeutic use for androgen-related acne.

A new method was developed to accurately measure enzyme activity related to prostate health.

This article updates a prior work on pharmacophore modeling and highlights the advances in 3D database searching technologies for drug design, without presenting new research findings.

This review discusses the mechanisms linking obesity and polycystic ovary syndrome and explores potential management options, but it presents no original research findings.

This study suggests that 5α-reduced glucocorticoids may have anti-inflammatory potential and could serve as biomarkers for liver inflammation in metabolic disease, with implications for drug development.

This review summarizes causes and treatments of androgenetic alopecia with a focus on herbs as potential alternatives, but reports no new results and suggests more research is needed to validate these options.